Erik Wiklund

Erik Wiklund

Company: Targovax

Job title: Chief Business Officer


Erik trained as a scientist specializing in cancer epigenetics research, and holds a PhD in molecular biology. After completing a postdoctoral fellowship, he transitioned to management consulting and joined the Pharma and Healthcare practice of McKinsey & Company. For the past 5 years he has held several positions in Norwegian biotech companies, including at Alegta, which developed and launched Xofigo in 2014. He joined Targovax as CFO in 2017, and transitioned into the CBO position in 2018.


Vaccinating Against Mutant RAS – Results from TG01 Phase I/II Trial 9:30 am

• Results from 32-patient TG01 trial in resected pancreatic cancer • Robust immune responses demonstrated against KRAS • Overview of clinical and molecular outcomesRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.